- Pirarubicin
-
-
2026-10-29
- CAS:72496-41-4
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Pirarubicin USP/EP/BP
-
- $1.10
-
2026-08-20
- CAS:72496-41-4
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons Min
- Pirarubicin
-
- $32.00
-
2026-07-15
- CAS:72496-41-4
- Purity: 99.15%
- Supply Ability: 10g
|
| | Pirarubicin Basic information |
| Product Name: | Pirarubicin | | Synonyms: | THP-ADM;THEPRUBICIN;(8s-cis)-droxyacetyl)-1-methoxy;(8S,10S)-10-[[3-Amino-2,3,6-trideoxy-4-O-[(2R)-tetrahydro-2H-pyran-2-yl]-a-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione;Tepirubicin;Therarubiein;THP-adriamycin;(8S,10S)-10-[(2S,4S,5S,6S)-4-Amino-6-methyl-5-[(2S)-oxan-2-yl]oxy-oxan-2-yl]oxy-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione | | CAS: | 72496-41-4 | | MF: | C32H37NO12 | | MW: | 627.64 | | EINECS: | | | Product Categories: | Intermediates & Fine Chemicals;Pharmaceuticals;Chiral Reagents;API;Inhibitors | | Mol File: | 72496-41-4.mol |  |
| | Pirarubicin Chemical Properties |
| Melting point | 188-192°C (dec.) | | alpha | D25 +175 ±25° (c = 0.2 in CHCl3) | | Boiling point | 834.7±65.0 °C(Predicted) | | density | 1.51±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | ethanol: soluble25mg/mL | | form | powder | | pka | 7.35±0.60(Predicted) | | color | Orange to Red | | Stability: | Hygroscopic | | InChIKey | KMSKQZKKOZQFFG-YXRRJAAWSA-N | | SMILES | C1=C(OC)C2C(=O)C3=C(O)C4[C@@H](O[C@@H]5O[C@@H](C)[C@@H](O[C@H]6OCCCC6)[C@@H](N)C5)C[C@](O)(C(CO)=O)CC=4C(O)=C3C(=O)C=2C=C1 |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-37/39 | | WGK Germany | 3 | | RTECS | QI9296000 | | Toxicity | LD50 i.v. in mice: 27.8 mg/kg (Umezawa, 1979) |
| | Pirarubicin Usage And Synthesis |
| Description | Pirarubicin is a new anthracycline anticancer agent structurally related to doxorubicin. In
acute leukemia, non-Hodgkin’s lymphoma, breast and ovariail carcinoma, pirarubicin is
reportedly superior to doxorubicin and better tolerated. Its major side-effect appears to be
myelosuppression, mainly in the form of leucopenia, which is potentially dose-limiting. | | Chemical Properties | Red Solid | | Originator | Meiji Seika (Japan) | | Uses | Structural analog of Doxorubicin. Antineoplastic. | | Definition | ChEBI: (7S,9S)-7-[[(2R,4S,5S,6S)-4-amino-6-methyl-5-[[(2R)-2-oxanyl]oxy]-2-oxanyl]oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione is an anthracycline. | | Brand name | Pinorubicin; Therarubucin |
| | Pirarubicin Preparation Products And Raw materials |
|